Glyxambi
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
  • Users Online: 432
  • Home
  • Print this page
  • Email this page


 
   Table of Contents      
ARTICLE
Year : 1987  |  Volume : 35  |  Issue : 4  |  Page : 216-217

Reversibility of Diabetic Maculopathy with Sulindac - A Case Report


,

Date of Web Publication20-Dec-2008

Correspondence Address:
Y R Sharma
,

Login to access the Email id

Source of Support: None, Conflict of Interest: None


PMID: 3506933

Rights and PermissionsRights and Permissions
  Abstract 

A patient of diabetic maculopathy was observed to achieve both subjective and objective improvement with short term sulindac therapy. No other such report in the literature is available regarding treatment of diabetic maculopathy with sulindac.


How to cite this article:
Sharma Y R, Madan M, Vajpayee R B, Tewari H E, Azad R V. Reversibility of Diabetic Maculopathy with Sulindac - A Case Report. Indian J Ophthalmol 1987;35:216-7

How to cite this URL:
Sharma Y R, Madan M, Vajpayee R B, Tewari H E, Azad R V. Reversibility of Diabetic Maculopathy with Sulindac - A Case Report. Indian J Ophthalmol [serial online] 1987 [cited 2019 Aug 24];35:216-7. Available from: http://www.ijo.in/text.asp?1987/35/4/216/26176


  Introduction Top


Diabetic maculopathyis the commonest cause of visual loss in Diabetics. There is no known medical therapy. Photocoagulation has shown to be effective in diabetic exudative maculopathy [1] . Sulindac has been suggested as a potential drug in treating certain diabetic complications like cataracts and retinopathyr [2] . Cunahvaz et al [3] demonstrated reversibility of retinal capillary leakage in early diabetic retinopathy using vitreous photofluorometry. We recently had an opportu­nity to use sulindac in a patient of diabetic maculopathy. Striking beneficial results obtained in this case are reported herein:


  Case Report Top


A 57 year old female school teacher with a history of diabetes for fourteen years controlled with Glibenclamide, presented with complaints of diminution of vision of six months duration Her best correctea vision was 6/18 OD and 6/9 OS. Over the next six months her vision deteriordted to 6/24 OD 6/12 OS. Fundus photography and fluorescein angiography revealed bilateral mode­rate diabetic maculopathy with microaneurysms, exudates, haemorrhages and focal leakage areas [Figure 1] Because of her profession she was greatly distressed specially on account of reading difficul­ties She was advised Argon Laser focal macular photocoagulation but she declined this and requested for any possible medical treatment Because of our interest in sulindac which we were using topically in cataract studies [2],[3] we tried this drug on this patient The drug was imported by the patient as it was not available in India. She was explained the experimental nature of the therapy and her consent was obtained She was put on 200 mgm bid.

After a months treatment her vision had improved to 6/12 OD 6/9 OS Near vision was N/5 in both eyes Repeat fundus photography and fluorescein angiography demonstrated objective improve­ment with lessening of microaneurysms, macular edema and exudates [Figure 2]. She continued to use Sulindac over the next two months and her vision recorded last was 6/12 OD and 6/6 OS. Thus there has been an objective improvement of two lines on Snellen's chart in each eye. Her near vision now is N/5 in both eyes.


  Discussion Top


We think it worthwhile to report this case because of striking rapid visual improvement on short term sulindac therapy and because improvement was both subjective and objective It does not seem to us that visual recovery could be coincidental. Her diabetes control remained unaffected during sulindac therapy. How sulindac might be benefi­cial in diabetic complications has been specul­ated [2],[3] and we suggest that it is worthwhile studying the use of sulindac in diabetic compli­cations like retinopathy and cataracts in large double blind studies This is the only potent aldose reductase inhibitor which is already in clinical use [2] .

 
  References Top

1.
Patz A, Schatz Ft Berkew JW etal : 1973 Trans Am Acaed Ophthalmol Otolaryngeol. 77: 34-39.  Back to cited text no. 1
    
2.
Sharma Y. R and Cotlier E: 1982 Exp. Eye Research. 35: 21-27.  Back to cited text no. 2
    
3.
Cunah-vaz J.G, Mota CC, Laite EC et al: 1985 Arch Ophthalmol 103: 1307-1311.  Back to cited text no. 3
    


    Figures

  [Figure 1], [Figure 2]



 

Top
 
 
  Search
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
Abstract
Introduction
Case Report
Discussion
References
Article Figures

 Article Access Statistics
    Viewed745    
    Printed40    
    Emailed0    
    PDF Downloaded0    
    Comments [Add]    

Recommend this journal